defibrotide
information and resources from the National Cancer Institute
NCI Thesaurus | defibrotide
A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties. Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium. NCI Thesaurus | defibrotide
A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties. Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium.
|
|
|
|
news articles
Gentium Receives First IRB Approval to Begin US Phase III Trial ... Mar 28, 2006
Genetic Engineering News, AMEX:GNT) (the Company) has received its first Institutional Review Board (IRB) approval to initiate a US Phase III clinical trial with Defibrotide for the ...
Gentium gets approval from institutions for VOD trial Mar 29, 2006
Pharmaceutical Business Review ...of the Dana-Farber/Harvard Cancer Center of Boston, Massachusetts, has given its approval for Gentium to initiate a phase III trial with defibrotide for the ...
TODAY ON PHARMALIVE.COM Dec 7, 2005
PharmaLive.com (press release), Final Data from Phase II Trial with Gentium's Defibrotide to be Presented at ASH Annual Meeting; Presentation by Dr. Richardson of Dana Farber Cancer Institute ...
Highlights of rising and falling US stocks Dec 7, 2005
Investor's Business Daily (subscription) Gentium SpA (GNT) reported positive data from its Phase II trial of Defibrotide for the treatment of veno-occlusive disease and multi-system organ failure as a ...
Gentium Elects David E. Kroin of Great Point Partners to Board Nov 29, 2005
Business Wire (press release), ...biotech investing world that will be of great benefit in helping guide the commercial development of our product candidates, particularly Defibrotide for the ...
|
|
